Search company, investor...

NextCure

Submit Your Analyst Briefing

nextcure.com

Founded Year

2015

Stage

IPO | IPO

Total Raised

$185M

Date of IPO

5/9/2019

Market Cap

0.08B

Stock Price

2.75

About NextCure

NextCure (NASDAQ: NXTC) is a biopharmaceutical company focused on discovering and developing immuno-oncology-based drugs. The Company is applying its platforms and know-how to identify biologically relevant targets and develop improved immunotherapy products.

Headquarters Location

9000 Virginia Manor Suite 200

Beltsville, Maryland, 20705,

United States

240-399-4900

Missing: NextCure's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: NextCure's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing NextCure

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

NextCure is included in 3 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

NextCure Patents

NextCure has filed 4 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/21/2017

7/19/2022

Clusters of differentiation, Immunology, Immune system, Transcription factors, Monoclonal antibodies

Grant

Application Date

9/21/2017

Grant Date

7/19/2022

Title

Related Topics

Clusters of differentiation, Immunology, Immune system, Transcription factors, Monoclonal antibodies

Status

Grant

Latest NextCure News

NextCure’s Clinical Development Strategy Centers People and Patients at the Core

Sep 27, 2022

NextCure (Nasdaq: NXTC), a growing clinical-stage biotechnology company nestled in Beltsville, Maryland, is setting the example. The company works to create novel immunomedicines to treat cancer and other immune-related diseases, and if you’ve read some of BioBuzz’s previous stories you should know by now that when NextCure says they are committed to something, they truly are committed. The post NextCure’s Clinical Development Strategy Centers People and Patients at the Core appeared first on BioBuzz.

NextCure Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

NextCure Rank

NextCure Frequently Asked Questions (FAQ)

  • When was NextCure founded?

    NextCure was founded in 2015.

  • Where is NextCure's headquarters?

    NextCure's headquarters is located at 9000 Virginia Manor, Beltsville.

  • What is NextCure's latest funding round?

    NextCure's latest funding round is IPO.

  • How much did NextCure raise?

    NextCure raised a total of $185M.

  • Who are the investors of NextCure?

    Investors of NextCure include Sofinnova Ventures, OrbiMed Advisors, Lilly Asia Ventures, Eli Lilly and Company, Alexandria Venture Investments and 13 more.

  • Who are NextCure's competitors?

    Competitors of NextCure include Epsilogen, OncoResponse, Immune-Onc Therapeutics, Fortis Therapeutics, Pionyr Immunotherapeutics and 9 more.

You May Also Like

OncoResponse Logo
OncoResponse

OncoResponse mines the human adaptive immune system to discover therapeutic antibodies against immuno-oncology targets. By identifying candidates from the immune systems of patients who have responded exceptionally well to cancer immunotherapies, OncoResponse has the potential to increase the success rate of these therapies across multiple cancer types.

I
ImmunoMet Therapeutics

ImmunoMet Therapeutics is a development-stage biotechnology company focused on utilizing cellular metabolism to develop anti-tumor and immuno-oncology therapies.

Immune-Onc Therapeutics Logo
Immune-Onc Therapeutics

Immune-Onc Therapeutics is a privately held cancer immunotherapy company dedicated to the discovery and development of biologic treatments for cancer patients. The company aims to translate scientific insights in the tumor microenvironment and immune suppressive pathways to develop biotherapeutics.

F
Fortis Therapeutics

Fortis Therapeutics is an immuno-oncology biotech company focused on developing new antibody-drug conjugate therapies for late-stage multiple myeloma and late-stage prostate cancer. Fortis was founded based on technology exclusively licensed from UCSF and developed in the laboratory of Bin Liu, Ph.D.

Pionyr Immunotherapeutics Logo
Pionyr Immunotherapeutics

Pionyr Immunotherapeutics is developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity. The company is exploiting target discovery and antibody generation platform technologies to create the next generation of immuno-oncology therapeutics. The company’s approach, Myeloid Tuning, is designed to enhance the immune system’s anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with high specificity.

Macrophage Pharma Logo
Macrophage Pharma

Macrophage Pharma is an immuno-oncology company focused on the discovery and development of novel therapies designed to enhance anti-tumour immune responses. The Company's technology platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner to activate the body's natural immune system to fight cancer.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.